Yingpai Pharmaceutical-B (07630) signed an exclusive licensing agreement with PHARMANOVIA for senapali in Europe, the Middle East and North Africa, Australia and New Zealand, and is expected to receive a total transaction consideration of up to 423.5 million euros

According to the Zhitong Finance App, Yingpai Pharmaceutical-B (07630) announced that the Group has entered into an exclusive cooperation with Pharmanovia (a global specialty pharmaceutical company that cooperates with innovative biotechnology companies and large pharmaceutical companies to provide patients with innovative specialty drugs) to grant Pharmanovia the exclusive right to manufacture, develop and commercialize senapali in Europe, the Middle East and North Africa, Australia and New Zealand for maintenance monotherapy for advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and peritoneal carcinoma.

Under licensing agreements relating to exclusive cooperation, the Group has granted Pharmanovia the exclusive right to manufacture, develop and commercialize Senapali in 66 countries for the maintenance monotherapy of advanced epithelial high-grade ovarian cancer, fallopian tube cancer and primary peritoneal cancer, including (among) all 27 EU member states, as well as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and the Middle East and North Africa countries.

The group is expected to receive a total of up to 423.5 million euros in transaction consideration, including down payment, recent registration milestone payments and commercialization milestone payments that have reached the corresponding sales threshold, and tiered royalties based on up to 20% (20% of the net sales) of the product.

The exclusive partnership marks the Group's first step in bringing its proven treatment solutions to patients outside of China, and expanding Senapali's business footprint to Europe, the Middle East and North Africa, as well as Australia and New Zealand. The Group will work closely with Pharmanovia to promote commercialization of Senapali in partner regions. With Pharmanovia's expertise and mature infrastructure, the company expects that after approval, Senapali will more quickly benefit target patients in partner regions and help provide high-quality treatment options to address unmet medical needs. This collaboration will not only enhance the product and the Group's global brand awareness, but will also further expand the Group's global commercialization strategy layout. The Group anticipates that this cooperation will have a positive and far-reaching impact on its development.

Furthermore, the marketing license application for senapalil for first-line maintenance treatment of adult patients with advanced ovarian cancer in Europe was officially accepted by the European Medicines Agency in August 2025 and is expected to be approved in the second half of 2026.